Molecular Vision Appoints Peter Woodford as Chairman
Strengthens Board in Preparation for Commercialisation
Mr Woodford has over 35 years’ experience in the diagnostics industry. Most recently he spent 15 years with Roche Diagnostics/Boehringer Mannheim, where he was responsible for a £1.2 billion budget for Roche Diabetes Care global strategic and commercial activities.
Molecular Vision’s previous Chairman, Dr Chris Wright, will continue to serve on the Board as a Non-Executive Director.
Other news from the department people
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.